[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lipocine Inc (LPCN)

Lipocine Inc (LPCN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,901
  • Shares Outstanding, K 8,244
  • Annual Sales, $ 1,980 K
  • Annual Income, $ -9,630 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 0.48
  • Price/Sales 9.22
  • Price/Cash Flow N/A
  • Price/Book 0.78

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.47
  • Number of Estimates 1
  • High Estimate $-0.47
  • Low Estimate $-0.47
  • Prior Year $-0.41
  • Growth Rate Est. (year over year) -14.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.05 unch
on 06/05/26
2.50 -18.00%
on 05/08/26
-0.28 (-12.02%)
since 05/05/26
3-Month
1.81 +13.26%
on 04/02/26
9.30 -77.96%
on 04/01/26
-6.14 (-74.97%)
since 03/05/26
52-Week
1.81 +13.26%
on 04/02/26
12.37 -83.43%
on 01/15/26
-1.07 (-34.34%)
since 06/05/25

Most Recent Stories

More News
Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154

Live webinar to take place on Friday, June 12, 2026 at 11:00 AM Eastern Time

LPCN : 2.05 (-7.24%)
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting

SALT LAKE CITY , May 19, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral...

LPCN : 2.05 (-7.24%)
Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase

SALT LAKE CITY , May 18, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral...

LPCN : 2.05 (-7.24%)
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026

SALT LAKE CITY , May 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral...

LPCN : 2.05 (-7.24%)
Lipocine: Q1 Earnings Snapshot

Lipocine: Q1 Earnings Snapshot

LPCN : 2.05 (-7.24%)
Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

SALT LAKE CITY , April 2, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective...

LPCN : 2.05 (-7.24%)
Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

SALT LAKE CITY , March 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective...

LPCN : 2.05 (-7.24%)
Lipocine: Q4 Earnings Snapshot

Lipocine: Q4 Earnings Snapshot

LPCN : 2.05 (-7.24%)
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)

SALT LAKE CITY , Feb. 18, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective...

LPCN : 2.05 (-7.24%)
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

SALT LAKE CITY , Jan. 20, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective...

LPCN : 2.05 (-7.24%)

Business Summary

Lipocine, Inc. is a specialty pharmaceutical company. It develops pharmaceutical products for use in men's and women's health. The Company's lead product candidate, LPCN 1021, is in Phase 3 and is targeted to treat symptoms of low testosterone for men in need of testosterone replacement therapy. Its...

See More

Key Turning Points

3rd Resistance Point 2.30
2nd Resistance Point 2.25
1st Resistance Point 2.15
Last Price 2.05
1st Support Level 2.00
2nd Support Level 1.95
3rd Support Level 1.85

See More

52-Week High 12.37
Fibonacci 61.8% 8.34
Fibonacci 50% 7.09
Fibonacci 38.2% 5.84
Last Price 2.05
52-Week Low 1.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.